 Home > Active Ingredient News > Immunology News > Ann Rheum Dis: Comparison of the occurrence of severe infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumor necrosis factor inhibitors

Ann Rheum Dis: Comparison of the occurrence of severe infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumor necrosis factor inhibitors

 Last Update: 2021-10-19
 Source: Internet
 Author: User

Tags

3 pi 4

sandhoff disease

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Recently, Annals of the Rheumatic Diseases, a top journal in the field of rheumatism, published a research article, researchers aiming to evaluate rheumatoid arthritis (RA) and psoriatic arthritis treated with tumor necrosis factor inhibitor (TNFi) (PsA) the incidence of severe infection (SI) in patients, and compare the risk of severe infection (SI) in RA patients and PsA patients
.

Rheumatoid arthritis infection

The researchers enrolled RA and PsA patients who had started TNFi treatment from the Norwegian-Disease Modification Antirheumatic Drug Registry, and calculated the rough incidence (IR) and IR ratios of SI
.

The researchers used an adjusted Cox regression model to compare the risk of SI in patients with RA and PsA

A total of 3169 TNFi treatment courses were identified in 2359 patients (RA/PsA: 1778/1391)
.

The age of RA patients has increased significantly, and a wider range of combination medications are used at the same time

The rough IR of SI for RA patients was 4.
17 (95% CI 3.
52 to 4.
95), and for PsA patients it was 2.
16 (95% CI 1.
66 to 2.
81)
.

In the complete set analysis, compared with RA patients, PsA patients had a lower risk of SI (HR 0.

It can be seen that compared with RA patients, PsA patients have a significantly lower risk of SI during TNFi treatment
.

Compared with RA patients, PsA patients have a significantly lower risk of SI during TNFi treatment
.

Original source:

Ingrid Egeland Christensen,et al.

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.